Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral drugs Clear all
Completed Phase 4 Interventional

A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence

NCT00785616
View directory record Official record
Conditions
HIV Infection
Interventions
MEMS cap monitoring
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

NCT01013415
View directory record Official record
Conditions
HIV-1 Infections
Interventions
HAART, T cells
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Early ART to Limit Infection and Establishment of Reservoir

NCT02859558
View directory record Official record
Conditions
HIV-1 Infection
Interventions
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional

Motivational Enhancement System for Adherence

NCT01009749
View directory record Official record
Conditions
HIV
Interventions
Motivational Enhancement System for Adherence (MESA), Motivational Enhancement System for Health (MESH)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 1 Interventional

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

NCT00000902
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 21 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

NCT00002453
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT00892437
View directory record Official record
Conditions
HIV-1 Infection
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

NCT00001075
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

NCT00005918
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 14, 2026, 6:02 AM EDT
Withdrawn No phase listed Observational

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

NCT01394133
View directory record Official record
Conditions
HIV Infected
Interventions
Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 14, 2026, 6:02 AM EDT
Not listed Phase 1 Interventional

The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00005120
View directory record Official record
Conditions
HIV Infections
Interventions
Calanolide A
Drug
Lead sponsor
Sarawak MediChem Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01108510
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 14, 2026, 6:02 AM EDT
Not listed Phase 3 Interventional

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
Drug · Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 6:02 AM EDT
Recruiting Phase 2 Interventional

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 6:02 AM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 14, 2026, 6:02 AM EDT
Completed No phase listed Observational

The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients

NCT00006442
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 14, 2026, 6:02 AM EDT
Not listed Phase 4 Interventional

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783
View directory record Official record
Conditions
HIV Infections, Obesity
Interventions
Biktarvy, Symtuza
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional

Text Messaging Intervention to Improve Retention in Care and Virologic Suppression in an Urban HIV-Infected Population

NCT01917994
View directory record Official record
Conditions
HIV, Patient Adherence, Mobile Technology
Interventions
Text Messages, Appointment Reminders
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional Results available

Care4Today v2.0 Application for Improving Adherence to HIV Medications

NCT02001064
View directory record Official record
Conditions
HIV, AIDS
Interventions
Care4Today v2.0 mobile application + electronic monitoring of adherence
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 6:02 AM EDT
Completed Phase 2 Interventional

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 14, 2026, 6:02 AM EDT
Not listed Phase 4 Interventional

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

NCT00005017
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 6:02 AM EDT
Terminated Phase 1 Interventional

Study of GS-1219 in Participants With HIV-1

NCT07115368
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-1219, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 14, 2026, 6:02 AM EDT